×

IL-1ra variants

  • US 7,619,066 B2
  • Filed: 04/01/2005
  • Issued: 11/17/2009
  • Est. Priority Date: 04/02/2004
  • Status: Active Grant
First Claim
Patent Images

1. A method of reducing aggregation of an aggregating interleukin-1 receptor antagonist (IL-1ra) comprising making a variant of an IL-1ra comprising the amino acid sequence set forth in SEQ ID NO:

  • 3,wherein the variant comprises an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO;

    3;

    wherein;

    a) the variant has an amino acid that does not have a charge at the position corresponding to Lysine-93 of SEQ ID NO;

    3;

    b) the variant has an amino acid that does not have a charge at the position corresponding to Arginine-97 of SEQ ID NO;

    3;

    orc) the variant has an amino acid that does not have a charge at the position corresponding to Lysine-93 of SEQ ID NO;

    3 and an amino acid that does not have a charge at the position corresponding to Arginine-97 of SEQ ID NO;

    3; and

    wherein if the variant has an arginine at the position corresponding to Arginine-97 of SEQ ID NO;

    3, the variant does not have a threonine or a histidine at the position corresponding to Lysine-93 of SEQ ID NO;

    3;

    thereby producing an IL-1ra having reduced aggregation.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×